Sign In
Buy MDWD
$13.73
-0.0300 (-0.218%)
At Close: Jun 03, 2026
MediWound Reports Fourth Quarter and Full-Year 2019 Financial Results
12:00pm, Tuesday, 25'th Feb 2020
Generated total full-year 2019 revenues of $31.8 million, driven primarily by Vericel license payment and development services to BARDA Initiated U.S. Phase 2 adaptive design.
MediWound Q4 EPS $(0.13) Misses $(0.1) Estimate, Sales $5.442M Beat $4.08M Estimate
12:00am, Tuesday, 25'th Feb 2020Vericel to Present at the 40th Annual Cowen Healthcare Conference on Monday, March 2, 2020
03:04pm, Monday, 24'th Feb 2020
CAMBRIDGE, Mass., Feb. 24, 2020 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that.
MediWound to Report Fourth Quarter & Fiscal 2019 Financial Results and Host a Conference Call and Webcast on February 25, 2020
01:00pm, Tuesday, 18'th Feb 2020
YAVNE, Israel, Feb. 18, 2020 -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn.
MediWound Expands its Distribution Agreement with GENFA MEDICA SA to Market NexoBrid in Ukraine and the Baltic States
01:00pm, Monday, 13'th Jan 2020
MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the expansion of its agree
MediWound Expands its Distribution Agreement with GENFA MEDICA SA to Market NexoBrid in Ukraine and the Baltic States
12:00am, Monday, 13'th Jan 2020BARDA Initiates the Procurement of NexoBrid for Emergency Response
11:30am, Monday, 06'th Jan 2020
MediWound Ltd. (MDWD) and its U.S. commercial partner Vericel Corporation (VCEL) today announced that the U.S. Biomedical Advanced Research and Development Authority (BARDA) within the Assistant Secre
If You Had Bought MediWound (NASDAQ:MDWD) Stock Five Years Ago, You'd Be Sitting On A 57% Loss, Today
04:29pm, Friday, 03'rd Jan 2020
Statistically speaking, long term investing is a profitable endeavour. But unfortunately, some companies simply don't...
MediWound Announces New Distribution Agreement In Australia, New Zealand And Singapore With Balance Medical
12:00am, Thursday, 02'nd Jan 2020MediWound Initiates US Phase 2 Adaptive Design Study of EscharEx for Treatment of Venous Leg Ulcers
12:00am, Tuesday, 03'rd Dec 2019MediWound Q3 EPS $(0.11) Beats $(0.15) Estimate, Sales $5.14M Beat $2.08M Estimate
12:00am, Thursday, 14'th Nov 2019Earnings Preview: MediWound (MDWD) Q3 Earnings Expected to Decline
12:00am, Thursday, 07'th Nov 2019Analysts Estimate MediWound (MDWD) to Report a Decline in Earnings: What to Look Out for
12:00am, Tuesday, 05'th Nov 2019Vericel Analyst Projects Wound Care Product Sales Will Grow Fivefold By 2025
07:09pm, Wednesday, 09'th Oct 2019
Vericel Corp (NASDAQ: VCEL ), a commercial-stage company that specializes in advanced cell therapies for treating patients with knee cartilage defects and severe burn wounds, is investment-worthy, acc
